Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 17, 2026 · Filed Mar 20, 2026
A board member of Corcept Therapeutics paid $2.5M out of pocket for Corcept Therapeutics shares. The Corcept Therapeutics shares held grew by 7%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$2,500,973
Shares × reported transaction price
$1M+
+7.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
21 days after results of Feb 24, 2026, 44 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.6% | −2.2% | +10.8% |
| 30 days | +33.8% | +9.3% | +24.5% |
| 90 days | +130.7% | +15.1% | +115.5% |
| 180 days | +222.8% | +16.3% | +206.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$819K of Corcept Therapeutics
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.